Igenica Biotherapeutics
Igenica Biotherapeutics
«Leveraging Dualsystems Biotech novel linker technology (LRC-TriCEPS) and its analytical data processing capabilities we were able to identify the heterophilic receptor for a highly-pursued immuno-oncology target.»
Dr. Edward van der Horst,
Senior Director, Preclinical Development
Igenica Biotherapeutics

2016-05-09T11:13:08+00:00
https://www.dualsystems.com/testimonials/lrc-triceps-service-4/